Welcome to CanView -
The BHC Ordering Portal

*I confirm I am 18 years or older, and I request further information about Medicinal Cannabis from CanView.

Yes, I am 18 years or older*

Medical Cannabis Distributor

Our Product Partners

Burleigh Heads Cannabis partners with leading domestic and international wholesale producers and suppliers with the goal to provide Australian patients with the widest range of Medical Cannabis products in the country. We ensure that each and every supply partner we work with aligns with our main core values and we work closely with them to make sure that all the Medical Cannabis products listed on CanView have reliable supply and conform to the highest quality standards.

If you are a cultivator, manufacturer, wholesaler, or brand looking for Australian market distribution of Medical Marijuana therapies or to increase your growth profile through our proven strategies, please get in touch with our team today. We look forward to speaking with you.

Register Now To Start Placing Orders



Medical Practitioner

Choose Medical Cannabis products, learn to prescribe & submit TGA SAS applications

Register

Pharmacist

View products, place orders and manage documentation.

Register

Tilray (NASDAQ:TLRY)

Tilray is a North American medicinal cannabis manufacturer based out of Canada with its GMP production facilities located in Nanaimo British Columbia and Catehande Portugal

Established in 2013, Tilray was the first GMP-certified medical cannabis producer to supply cannabis extract products to thousands of patients, physicians, pharmacies, hospitals, governments, and researchers on four continents.

Tilray Australia and New Zealand were established in 2017 and are dedicated to supporting healthcare professionals, patients, governments, and hospitals in the ANZ region with access to their GMP medicinal cannabis products.

Tilray was the first company to legally export medicinal cannabis from North America to Australia and New Zealand. Today, it is one of the leading providers of medicinal cannabis in Australia and New Zealand for commercial, compassionate access and research purposes.

The Tilray and Burleigh Heads Cannabis partnership is all about improving patient access and customer experience. Via our online ordering portal, Healthcare Practitioners and Pharmacists have access to the extensive Tilray GMP range.

NSW, Australia

Cronos Australia: (ASX:CAU)

Cronos Australia (ASX:CAU) is committed to providing Australian patients access to the highest quality medicinal cannabis products. The company has the vision to become a leading health and wellness company in the Asia Pacific region with a portfolio of cannabinoid products – including THC and CBD.

Cronos Australia’s flagship brand is the Adaya Medicinal Cannabis range. The Adaya range has been designed, developed, and formulated based on feedback from patients and healthcare professionals to meet their needs throughout Australia. There is also an important focus on low product costs, which directly underpins the goal of sustainable patient access.

We are working closely with the Cronos Australia team on one of the critical pain points for both doctors and patients which is stock availability. We are confident of the Adaya supply chain so that patients, doctors, and pharmacists can rest assured Adaya products don't run out of stock.

NSW, Australia

Little Green Pharma (ASX:LGP)

Little Green Pharma (LGP) is the first Australian company to grow and produce Australian medical-grade cannabis oil and has been assisting patients since 2018 with a vision to transform the lives of patients.

LGP produces locally-manufactured, quality cannabis medicines that are AU GMP certified. They stand proudly behind the Made in Australia stamp having experienced first-hand the strict quality requirements for medicinal cannabis products grown and manufactured locally to Australian standards and the assurance this gives to both doctors and patients.

The Little Green Pharma team has proven their commitment to helping patients which shines through not only through the quality, reliability, and affordability of their products, but the level of service they provide as well.

WA, Australia

BOD Australia (ASX:BDA)

BOD Australia is an ASX-listed company committed to providing the highest quality cannabinoid extracts to support patient care. The BOD Australia journey started in 2014, with a simple vision to innovate and create herbal-based healthcare products, backed by science and demonstrated evidence, bringing the best that both science and herbal medicine has to offer. The companies ongoing aim is to provide their customers with the highest quality ingredients and apply evidence-based scientific rigour and clinical trial processes to ensure real solutions for all

BOD have collaborated with world-renowned manufacturers to provide GMP pharmaceutical-grade Medicinal Cannabis under their MediCabilis range. They have ongoing partnerships with with world-renowned researchers, doctors and institutions to build knowledge and evidence in the use of medical cannabis for the MediCabilis brand

NSW, Australia

Australian Naturals Therapeutics Group (ANTG)

ANTG produces exclusive high-quality cannabinoid-based medicinal treatments that can meet individual patient needs. The ANTG team reports that they have witnessed first-hand the power of medicinal cannabis in relieving chronic and debilitating disease symptoms in areas where traditional treatments lack efficacy and or have significant side effects.

The company's focus is on putting the needs of patients first – and they firmly believe, as an independent company, that they are uniquely positioned to achieve more. That’s why ANTG is committed to investing in research and development, both in-house as well as partnering with key universities to undertake cannabis research and support clinical trial programs.

NSW, Australia

MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based biopharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high-quality phytocannabinoid-derived medicines for the growing demand in the medical markets in Europe, North America, and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

MGC Pharma has a number of research collaborations with world-renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

WA, Australia

MedCan Australia

Medcan Australia was granted the 13th Cultivation and Production licence from the Office of Drug Control in November 2017 and was brought to life with a single vision to provide Australian patients with a high quality, fair priced product, which has now positioned the company to be a front runner in the Australia Medicinal Cannabis Industry.

With a vertically integrated model, Medcan Australia will Cultivate, Produce and Manufacture high-quality medicinal cannabis products for both clinical trials and individual patient access. Their automated cultivation processes are designed to ensure consistent results so consumers are assured the quality, composition, and reliability of their supply

Medcan Australia believe Medicinal Cannabis is not simply a "one pill suits all" solution. Individual patients have specific needs and requirements and we aim to provide a specific product based on a patient's specific set of circumstances.

QLD, Australia

Load More

Cannatrek

The Cannatrek Group currently possesses all federal government medicinal cannabis licences, and was the second company to obtain a Cannabis Research license to import seed, cultivate and manufacture a diverse range of medical cannabis products.
Cannatrek is set to redefine the medical cannabis industry in Australia, by converging research, cultivation, green technology and distribution, that will put patients first and create a sustainable domestic enterprise, underpinned by smart global partnerships.

VIC, Australia

Beacon Medical

Beacon Medical Australia was established from its listed Canadian parent company VIVO Cannabis who has been growing and selling pharmaceutical-grade medical cannabis to patients since 2014.
The name and logo is after the symbol of hope and relief for those seeding guidance, which is why it is the perfect name for the brand. Beacon Medical’s hope is that it will become a guiding light for patients and they are doing everything in their power to make that a reality.
The state of the art indoor growing facilities are precision controlled environments and some of the most technologically advanced in the world. The highly experienced cultivation team is able to manipulate the key plant growth variables for each strain to ensure they consistently produce the highest quality products for patient needs.

ON, Canada

Burleigh Heads Cannabis (BHC)

Burleigh Heads Cannabis was one of the very first companies in Australia to receive its importation and wholesale license for Medical Cannabis back in 2017. Since then they have grown into one of the countries largest and most well-known wholesalers, now selling thousands of products per month to an ever-growing network of pharmacies.

BHC partners with both domestic and international suppliers to offer pharmacies and their patients the widest range of Medical Cannabis products available in Australia. This provides a one-stop solution for all ordering and distribution needs.

QLD, Australia

Sunco Green

Sunco Green was established to address the need for patient access to the clinical benefits of medical cannabis. Their aim is to provide a high-quality product range designed to be flexible as the needs of the patients change and as the experience of the prescribers expands. Their mission is to build a sustainable business in a socially responsible and environmentally aware way that will be part of the local Australian cannabis community and the wider cannabis industry for the next decades and beyond.

QLD, Australia

Cannim (Brand Name: Lumir)

Established in 2017, Cannim was founded on the vision of bringing the benefits of medicinal cannabis to the world. Since that time, Cannim has invested in farms in Australia and Jamaica and built a network of EU GMP (Good Manufacturing Practice) manufacturers. The business is built on the three key pillars of Safety, Science, and Scale and it is focused on developing products to pharmaceutical standards for the global market. This long-term vision is integral to Cannim’s sustainable approach to building its global market share and establishing world-leading medicinal cannabis brands.

Leading cannabis researcher Professor Lumir Hanus sits on Cannim’s advisory board and the flagship brand bears his name.

NSW, Australia

SatiVite Pty Ltd

SatiVite is a different kind of medical cannabis company, one created by experienced farmers, innovators, researchers and patients – not in a boardroom. Our mission is simple: to consistently provide the best, sustainably produced medical cannabis products to patients in Australia and beyond.

At Sativite, we believe that all medical treatments should be personalised. That’s why we work closely with medical cannabis specialists, family doctors, pharmacists and other healthcare professionals to seek out and deliver a wide variety of high-quality products at affordable prices.

QLD, Australia

Gamma Biomedical

Founded in 2014, Gamma Biomedical specialises in disrupting existing markets to provide easy, more affordable access to biomedical products. A multinational organisation, headquartered in Australia, our goal is to improve access to products and services that haven’t been previously available to Australian health care providers.

Gamma Biomedical holds a range of medical wholesale licenses that cover the broad gamut of scheduled medicines in Australia. We have extensive, multi-year, experience with international health regulations and logistics, ensuring governmental compliance and smooth, consistent, supply chains.

Isospec, our CBD range of products, was developed in close collaboration with leading medical scientists, physicians and elite athletes in the United States with the goal of maximizing natural healing and recovery. Isospec is also the first range of CBD products to offer flavoured oils and topical products in Australia. Controlling every step from seed to final finished product allows for constant improvement and innovation at every step of production. Manufacturing under stringent GMP controls helps guarantee a premium therapeutic product for patients.

Isospec has a strong pipeline of new products slated to launch in the coming year. In addition, Gamma is in the final stages of adding a THC focussed brand to our catalogue of medicines that will be commercially available by 2022.

QLD, Australia

Load More

Cymra Life Sciences

Cymra is a Australian owned medical cannabis cultivator and manufacturer based in Byron Bay, NSW. Established in 2017 its founders set out to improve the lives of patients through low cost high quality GMP medicines grown and manufactured in Australia.

Cymra’s approach is to create formulations specific to conditions such as pain and anxiety using the best and highly efficacious products that are full spectrum, providing a product that is more like the plant, including terpenes and other beneficial compounds.

The company has clinical trials currently running across chronic pain and have invested in local Australian research and people to help execute in the Byron region. Too many people have lost their lives to opiate medication for long term chronic pain and Cymra’s mission is to provide evidence to support cannabis as a replacement for opiates.

Cymra uses organic farming practices at their site to produce high quality flower and ingredients that provide patients the cleanest, safest, most effective products on the market.

The Cymra and Burleigh Heads Cannabis partnership is all about improving patient access and customer experience and education.

NSW, Australia